Holen Sie sich die Stockscreener-App
8.94
3.35%
-0.31
Handel nachbörslich:
9.42
0.48
+5.37%
Schlusskurs vom Vortag:
$9.25
Offen:
$9.34
24-Stunden-Volumen:
1.21M
Relative Volume:
0.51
Marktkapitalisierung:
$917.92M
Einnahmen:
$187.64M
Nettoeinkommen (Verlust:
$-95.00M
KGV:
-9.4105
EPS:
-0.95
Netto-Cashflow:
$-69.02M
1W Leistung:
+1.02%
1M Leistung:
+8.36%
6M Leistung:
+27.71%
1J Leistung:
-26.72%
1-Tages-Spanne:
$8.92
$9.58
1-Wochen-Bereich:
$8.35
$9.7112
52-Wochen-Spanne:
$5.635
$13.53
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Firmenname
Day One Biopharmaceuticals Inc
Sektor
Branche
Telefon
650 484-0899
Adresse
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Vergleichen Sie DAWN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
8.94 | 949.75M | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-09 | Bestätigt | Needham | Buy |
| 2024-08-01 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-04-24 | Bestätigt | Needham | Buy |
| 2023-04-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-08 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-03 | Eingeleitet | Oppenheimer | Perform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
Alle ansehen
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
Trading Action: Is Day One Biopharmaceuticals Inc. stock a good choice for value investorsWall Street Watch & Technical Buy Zone Confirmation - ulpravda.ru
Will Day One Biopharmaceuticals Inc. stock benefit from automation2025 Bull vs Bear & Free Accurate Trade Setup Notifications - ulpravda.ru
Day One concludes Mersana Therapeutics acquisition - Yahoo Finance
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Day One Biopharmaceuticals Signs Contingent Value Rights Agreement With Computershare - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
Day One buys Mersana to advance drug for rare salivary cancer - Stock Titan
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Index Biomarker Science - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
(DAWN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
When Can We Expect A Profit From Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)? - 富途牛牛
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
Is Day One Biopharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Price-Driven Insight from (DAWN) for Rule-Based Strategy - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 6%What's Next? - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Sahm
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026I'm Bullish (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Day One Biopharmaceuticals Reports Promising FIREFLY-1 Trial Results - timothysykes.com
FuelCell Energy Posts Strong Q4 Results, Joins Trump Media & Technology, Micron Technology, Lululemon And Other Big Stocks Moving Higher On Thursday - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Gains Visibility Nasdaq Today - Kalkine Media
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.5%Still a Buy? - MarketBeat
Day One Biopharmaceuticals Target of Unusually Large Options Trading (NASDAQ:DAWN) - MarketBeat
Day One Biopharma (DAWN) announces positive 3-year follow-up results from pivotal phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) - MSN
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Hudson Bay Capital Management LP Has $8.43 Million Holdings in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) - Finviz
20 Stocks That Will Double in 2026 - Insider Monkey
Halper Sadeh LLC Encourages FFWM, MRSN, FSUN Shareholders to Contact the Firm to Discuss Their Rights - FinancialContent
Braidwell LP Has $14.18 Million Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals Reports Strong Q3 2025 Results - MSN
Day One Biopharmaceuticals Inc. (DAWN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Day One Biopharmaceuticals Reports Strong Q3 2025 Growth - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 4.9%What's Next? - MarketBeat
Why The Narrative Around Day One Biopharmaceuticals Is Shifting After The Mersana Acquisition - Yahoo Finance
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
(DAWN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Day One’s FIREFLY Trial Shows Promise in Pediatric Cancer Treatment - timothysykes.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Futures Clinical-Stage Innovation - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
180,133 Shares in Day One Biopharmaceuticals, Inc. $DAWN Bought by Schroder Investment Management Group - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Updated FIREFLY-1 Data Further Support Tovorafenib as a SOC in R/R Pediatric Low-Grade Glioma - OncLive
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Virtus Investment Advisers LLC - MarketBeat
Finanzdaten der Day One Biopharmaceuticals Inc-Aktie (DAWN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):